Treating Crohn’s disease: at “deep” remission and exploring beyond

Crispin Corte and Warwick S Selby
Med J Aust 2012; 197 (8): . || doi: 10.5694/mja12.11419
Published online: 15 October 2012

A new treatment target includes mucosal healing as well as clinical remission

In the late 1990s, controlled trials confirmed the efficacy of tumour necrosis factor-alpha (TNF-α) antibodies in treating active Crohn’s disease, signalling a major breakthrough in treatment. TNF-α monoclonal antibody therapy has since been shown to lead to significant improvements in quality of life and symptom control and a decrease in the need for surgery and prolonged hospitalisation for patients with Crohn’s disease.1 The development of such an effective form of treatment has led not only to a change in the paradigm for treating Crohn’s disease, but also to an increasing awareness of its limitations.

  • Crispin Corte1
  • Warwick S Selby2,3

  • 1 John Radcliffe Hospital, Oxford, UK.
  • 2 Royal Prince Alfred Hospital, Sydney, NSW.
  • 3 Central Clinical School, Faculty of Medicine, University of Sydney, Sydney, NSW.


Competing interests:

Warwick Selby is on the advisory board of Abbott.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.